ZA200208761B - Pharmaceutical form of administration for peptides, methods for its production and use. - Google Patents

Pharmaceutical form of administration for peptides, methods for its production and use.

Info

Publication number
ZA200208761B
ZA200208761B ZA200208761A ZA200208761A ZA200208761B ZA 200208761 B ZA200208761 B ZA 200208761B ZA 200208761 A ZA200208761 A ZA 200208761A ZA 200208761 A ZA200208761 A ZA 200208761A ZA 200208761 B ZA200208761 B ZA 200208761B
Authority
ZA
South Africa
Prior art keywords
peptides
administration
production
methods
pharmaceutical form
Prior art date
Application number
ZA200208761A
Other languages
English (en)
Inventor
Horst Bauer
Michael Damm
Werner Sarlikiotis
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Publication of ZA200208761B publication Critical patent/ZA200208761B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200208761A 2000-05-18 2002-10-30 Pharmaceutical form of administration for peptides, methods for its production and use. ZA200208761B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10024451A DE10024451A1 (de) 2000-05-18 2000-05-18 Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
ZA200208761B true ZA200208761B (en) 2002-11-29

Family

ID=7642584

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200208761A ZA200208761B (en) 2000-05-18 2002-10-30 Pharmaceutical form of administration for peptides, methods for its production and use.

Country Status (25)

Country Link
US (2) US7718599B2 (fr)
EP (1) EP1282400B1 (fr)
JP (2) JP4944340B2 (fr)
KR (1) KR100580142B1 (fr)
CN (1) CN100342908C (fr)
AR (1) AR028588A1 (fr)
AU (1) AU777185B2 (fr)
BG (1) BG65976B1 (fr)
BR (1) BR0110892A (fr)
CA (1) CA2348167C (fr)
CZ (1) CZ303981B6 (fr)
DE (1) DE10024451A1 (fr)
HK (1) HK1058622A1 (fr)
HU (1) HUP0302050A3 (fr)
IL (1) IL152479A (fr)
MX (1) MXPA02011389A (fr)
NO (1) NO20025277L (fr)
NZ (1) NZ522381A (fr)
PL (1) PL203958B1 (fr)
RU (1) RU2253438C2 (fr)
SK (1) SK288118B6 (fr)
TW (1) TWI243059B (fr)
UA (1) UA74578C2 (fr)
WO (1) WO2001087265A2 (fr)
ZA (1) ZA200208761B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
JP4940492B2 (ja) * 2000-09-04 2012-05-30 大正製薬株式会社 鉄化合物配合内服液剤
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
RS20050247A (en) * 2002-09-27 2007-06-04 Zentaris Gmbh., Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
ATE381945T1 (de) * 2004-03-12 2008-01-15 Intercell Ag Verfahren zur solubilisierung von peptid- mischungen
EP1674082A1 (fr) * 2004-12-22 2006-06-28 Zentaris GmbH Procédé pour la manufacture des suspensions ou lyophilisates steriles des complexes mal-soluble de peptides basic, des formulations pharmaceutiques avec ces complexes et leur utilisation comme medicament
RU2358721C1 (ru) * 2005-04-15 2009-06-20 Виктор Павлович Кутняк Антинеопластический препарат (варианты)
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
BR112013013903A2 (pt) * 2010-12-06 2016-09-13 Astron Res Ltd preparação farmacêutica aquosa estável pronta para uso de cetrorelix para administração parenteral, processo para a fabricação de uma preparação farmacêutica aquosa estável pronta para uso de cetrorelix para uso de cetrorelix para administração parenteral
CN102144980B (zh) * 2011-03-07 2013-01-09 深圳市健元医药科技有限公司 一种更加稳定的lhrh拮抗剂冻干粉针剂
WO2015158823A1 (fr) * 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Composition pharmaceutique vétérinaire et utilisation de ladite composition pharmaceutique vétérinaire
DK3576771T3 (da) * 2017-01-31 2022-05-30 Veru Inc Sammensætninger og fremgangsmåder til langvarig frigivelse af antagonister for gonadotropin-frigivende hormon (gnrh)
WO2020254952A1 (fr) * 2019-06-17 2020-12-24 Intas Pharmaceuticals Ltd. Formulation stable de cétrorélix
PL3811927T3 (pl) 2019-10-24 2022-02-07 Sun Pharmaceutical Industries Ltd Trwała pozajelitowa postać dawkowania octanu cetroreliksu
WO2022269572A1 (fr) 2021-06-25 2022-12-29 Extrovis Ag Compositions pharmaceutiques
WO2023017326A1 (fr) * 2021-08-11 2023-02-16 Rk Pharma Inc. Compositions prêtes à l'emploi d'acétate de cétrorélix

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE141996C (fr)
DD141996A1 (de) * 1979-02-21 1980-06-04 Ingrid Wolf Verfahren zur herstellung von lyophilisierten lhrh-praeparationen
JPS5892620A (ja) * 1981-11-28 1983-06-02 Sunstar Inc インタ−フエロン安定配合組成物
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
DK163689A (da) * 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
JPH0725662B2 (ja) * 1990-10-22 1995-03-22 アース製薬株式会社 使用時調製型上皮細胞成長因子含有水性薬剤の安定化方法
US5643878A (en) * 1991-09-12 1997-07-01 Ciba-Geigy Corporation 5-amino-4-hydroxyhexanoic acid derivatives
JP3608802B2 (ja) * 1991-09-20 2005-01-12 第一サントリーファーマ株式会社 安定なカルシトニン医薬組成物及びその製造法
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
JPH08502492A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 治療用ミクロエマルジョン
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
JP3636480B2 (ja) * 1993-05-19 2005-04-06 科研製薬株式会社 凍結乾燥製剤
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP2915296B2 (ja) * 1993-08-30 1999-07-05 宇野 潤 抗真菌製剤
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
ATE197398T1 (de) * 1994-09-09 2000-11-11 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0726075A1 (fr) * 1995-02-08 1996-08-14 Therapicon Srl Solutions pharmaceutiques salines non-inorganiques pour administration endonasale
CA2214889C (fr) * 1995-03-10 2005-05-24 Hans Koll Formes galeniques pharmaceutiques contenant un polypeptide, sous forme de microparticules, et leur procede de preparation
DE19542837A1 (de) * 1995-11-17 1997-05-22 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung
US5942493A (en) * 1995-11-28 1999-08-24 Asta Medica Aktiengesellschaft LH-RH antagonists having improved action
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
IT1282733B1 (it) * 1996-05-20 1998-03-31 Flarer S A Composizioni farmaceutiche contenenti ciclosporina ed un veicolante comprendente almeno un estere dell'acido alfa-glicerofosforico
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
WO1998032423A1 (fr) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Microspheres a liberation prolongee, leur production et utilisation
EP1021177A4 (fr) * 1997-02-04 2002-05-15 John V Kosbab Compositions et procedes destines a la prevention et au traitement de maladies degeneratives vasculaires
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US20030162721A1 (en) * 1997-07-07 2003-08-28 Francesco Mehlem Pharmaceutical composition containing peptichemio
JP3895109B2 (ja) * 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
WO2000015241A1 (fr) * 1998-09-11 2000-03-23 Chugai Seiyaku Kabushiki Kaisha Preparation d'une solution proteinique et son procede de stabilisation
EP0998940A1 (fr) * 1998-09-30 2000-05-10 Laboratoire Theramex Compositions pharmaceutiques à base de alpha-cyclodextrine pour administration orale d'analogues de LH-RH
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6911455B2 (en) * 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations

Also Published As

Publication number Publication date
BR0110892A (pt) 2003-03-11
US20050159335A1 (en) 2005-07-21
JP4944340B2 (ja) 2012-05-30
AU7404101A (en) 2001-11-26
AU777185B2 (en) 2004-10-07
CN100342908C (zh) 2007-10-17
EP1282400A2 (fr) 2003-02-12
KR100580142B1 (ko) 2006-05-16
MXPA02011389A (es) 2003-04-25
SK288118B6 (sk) 2013-09-03
JP2003533466A (ja) 2003-11-11
RU2253438C2 (ru) 2005-06-10
TWI243059B (en) 2005-11-11
WO2001087265A3 (fr) 2002-04-18
UA74578C2 (uk) 2006-01-16
CZ20023969A3 (cs) 2003-05-14
HK1058622A1 (en) 2004-05-28
NO20025277D0 (no) 2002-11-04
BG107312A (bg) 2003-06-30
KR20030036179A (ko) 2003-05-09
NO20025277L (no) 2002-11-04
PL363007A1 (en) 2004-11-15
CA2348167C (fr) 2012-01-10
BG65976B1 (bg) 2010-08-31
WO2001087265A2 (fr) 2001-11-22
HUP0302050A2 (hu) 2003-09-29
AR028588A1 (es) 2003-05-14
EP1282400B1 (fr) 2016-12-14
PL203958B1 (pl) 2009-11-30
IL152479A (en) 2013-08-29
US7718599B2 (en) 2010-05-18
AU777185C (en) 2001-11-26
IL152479A0 (en) 2003-05-29
CZ303981B6 (cs) 2013-07-31
CA2348167A1 (fr) 2001-11-18
US20020039996A1 (en) 2002-04-04
US7696149B2 (en) 2010-04-13
CN1469734A (zh) 2004-01-21
NZ522381A (en) 2004-07-30
JP2011213733A (ja) 2011-10-27
DE10024451A1 (de) 2001-11-29
HUP0302050A3 (en) 2012-11-28
SK17162002A3 (sk) 2003-07-01

Similar Documents

Publication Publication Date Title
AU2682401A (en) Flavonoid drug and dosage form, its production and use
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
HK1077832A1 (en) 17a-ALKYL-17ß-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE FRODUCTION THEREOF, AND USE OF SAID 17a-ALKYL-17ß-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
ZA200109859B (en) 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations.
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containingthe same.
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
IL154012A0 (en) Hydrogel-driven drug dosage form
HUP0300209A3 (en) Lipid nanocapsules, preparation method and use as medicine
HK1068812A1 (en) Drug preparations
CZ20023753A3 (cs) Substituované thioacetamidy, jejich použití pro výrobu léčiva a farmaceutický prostředek s jejich obsahem
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
GB0017060D0 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
SG116507A1 (en) Pharmaceutical dosage form and method of making.
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
AU2001295483A1 (en) Solid peptide preparations for inhalation, and the production thereof
ZA200203294B (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them.
HUP0300222A3 (en) Novel lhrh-antagonists, production and use thereof as medicament
ZA200300777B (en) Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts.
IL145041A (en) Morpholine derivatives, methods for the production thereof and pharmaceutical preparations
AU2001254812A1 (en) 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations
AU2002210439A1 (en) Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts
HK1047037A1 (en) Pharmaceutical preparations containing nanosols ofchitosan, and their preparation.
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
MXPA03006162A (es) Derivados de mikanolida, su preparacion y sus usos terapeuticos.